Expected Moves

Market expectations for a definitive FDA pathway update regarding buntanetap's next clinical steps for Alzheimer's/Parkinson's. From a $1.85 baseline, clear phase 3 authorization upside is massive, while delay drives significant downside.

Q3 2026 earnings announcement focusing on quarterly cash burn rates and remaining runway. Starting from $1.20, any upside surprise in cost controls targets $1.80, whereas cash depletion fears push shares to $0.80.

Anticipated readout or official commencement of the next pivotal trial phase for buntanetap. Anchored at $0.35, successful clinical momentum yields a dramatic multi-bagger target of $1.20, whereas failure leads to a terminal $0.20 floor.

Expected timeline for a secondary equity offering or ATM utilization to fund remaining clinical obligations. From a $0.80 anchor, successful non-toxic placement targets $1.10, but a deeply discounted warrant-heavy raise forces a $0.50 fallback.

Year-end 2026 financial reporting providing the official 10-K outlook. Assuming a deeply depressed $0.50 entry, favorable 2027 guidance points to $0.90, while 'going concern' language triggers a drop to $0.35.

First quarter results focusing on operating expenses trailing the spring clinical update. From a $1.20 level, steady execution sees $1.60, while accelerated R&D spend drags the stock back to $0.80.

Mid-year financial check-in assessing clinical progression vs. treasury. An entry of $1.60 allows a target of $2.10 on continued narrative momentum, while funding reality-checks force a $1.10 fallback.